Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) Short Interest Down 10.0% in November

Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) was the target of a large decrease in short interest during the month of November. As of November 30th, there was short interest totalling 900 shares, a decrease of 10.0% from the November 15th total of 1,000 shares. Based on an average daily volume of 30,300 shares, the short-interest ratio is presently 0.0 days.

Emmaus Life Sciences Stock Up 93.3 %

Shares of OTCMKTS:EMMA traded up $0.01 during trading on Monday, hitting $0.01. The stock had a trading volume of 153,511 shares, compared to its average volume of 37,951. The company has a market capitalization of $827,064.70, a PE ratio of -0.07 and a beta of 6.20. The firm’s fifty day moving average is $0.03 and its 200 day moving average is $0.04. Emmaus Life Sciences has a 12 month low of $0.00 and a 12 month high of $0.13.

About Emmaus Life Sciences

Emmaus Life Sciences, Inc, a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.